LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Aktien・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

87.86 2.48

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

84.39

Max

89.3

Schlüsselkennzahlen
By Trading Economics
Einkommen	-8.1M -56M
Verkäufe	2.9M 60M
EPS	-0.83
Gewinnspanne	-92.559
Angestellte	414
EBITDA	-9.7M -52M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+58.3% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	126M 6B
Vorheriger Eröffnungskurs	85.38
Vorheriger Schlusskurs	87.86

Nachrichtenstimmung

By Acuity

46%

54%

149 / 344 Ranking in Healthcare

Rhythm Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Juni 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9. Juni 2026, 23:45 UTC

Akquisitionen, Fusionen, Übernahmen

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9. Juni 2026, 23:44 UTC

Akquisitionen, Fusionen, Übernahmen

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9. Juni 2026, 23:44 UTC

Akquisitionen, Fusionen, Übernahmen

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9. Juni 2026, 23:43 UTC

Akquisitionen, Fusionen, Übernahmen

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9. Juni 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9. Juni 2026, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9. Juni 2026, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9. Juni 2026, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung: Additional Investment Makes It Largest Shareholder in Element

9. Juni 2026, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9. Juni 2026, 20:51 UTC

Ergebnisse

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. Juni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Juni 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9. Juni 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9. Juni 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9. Juni 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9. Juni 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9. Juni 2026, 18:52 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9. Juni 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9. Juni 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9. Juni 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9. Juni 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9. Juni 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9. Juni 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. Juni 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Juni 2026, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

9. Juni 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9. Juni 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer-Vergleich

Kursveränderung

Rhythm Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

58.3% Vorteil

12-Monats-Prognose

Durchschnitt 136.77 USD 58.3%

Hoch 158 USD

Tief 105 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Rhythm Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

Buy

Halten

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Rhythm Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

149 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.